Deutsche Bank downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Buy to Hold with a price target of $17.00 (from $71.00). Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Downgrades Hot Downgrades

FBR Capital Slashes Sarepta (SRPT) Price Target, But Remains 49% Above Current LevelsNovember 12, 2013 2:45 PM Sarepta (SRPT) Target Cut to $45 at Wedbush, Analyst Expects Larger Eteplirsen TrialNovember 12, 2013 2:22 PM Needham & Company Downgrades Sarepta Therapeutic (SRPT) to HoldNovember 12, 2013 12:46 PM Sarepta (SRPT) Eteplirsen Delay Impacts DCF by $10/sh Each Year - Deutsche BankNovember 12, 2013 9:25 AM Piper Jaffray Downgrades Sarepta Therapeutic (SRPT) to UnderweightNovember 12, 2013 8:11 AM FDA Considers Sarepta's (SRPT) NDA for Eteplirsen 'Premature'November 12, 2013 7:05 AM